<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564029</url>
  </required_header>
  <id_info>
    <org_study_id>B7431005</org_study_id>
    <nct_id>NCT02564029</nct_id>
  </id_info>
  <brief_title>PF-06372865 in Subjects With Photosensitive Epilepsy</brief_title>
  <official_title>A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-06372865 in subjects with photosensitive epilepsy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2015</start_date>
  <completion_date type="Actual">February 7, 2017</completion_date>
  <primary_completion_date type="Actual">January 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PF-06372865 to reduce photosensitive range in subjects with documented photoepilepsy in their most sensitive eye state</measure>
    <time_frame>0, 1, 2, 4, 6 hours post-dose</time_frame>
    <description>The Standardized Photosensitivity Range (SPR) in the subject's most sensitive eye condition as measured by the Least Squares mean SPR averaged across all post-dose time points (up to 6 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the ability of PF-06372865 to demonstrate ant-convulsive efficacy for pre-specified secondary endpoints in subjects with documented photosensitive epilepsy</measure>
    <time_frame>0, 1, 2, 4 and 6 hours post-dose</time_frame>
    <description>The proportion of subjects with complete suppression, partial response, and no response to intermittent photic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the ability of PF-06372865 to demonstrate anti-convulsive efficacy for pre-specified secondary endpoints in subjects with documented photosensitive epilepsy</measure>
    <time_frame>0, 1, 2, 4 and 6 hours post-dose</time_frame>
    <description>The Standardized Photosensitivity Range (SPR) in the eyes closed, eye closure, and eyes open condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose maximum observed plasma concentration (Cmax) of PF-06372865</measure>
    <time_frame>0, 1, 2, 3, 4, and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose area under the curve from time zero to last quantifiable concentration [AUC (last)] of PF-06372865</measure>
    <time_frame>0, 1, 2, 3, 4 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose time to reach maximum observed plasma concentration (Tmax) of PF-06372865</measure>
    <time_frame>0, 1, 2, 3, 4 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose plasma concentration of lorazepam</measure>
    <time_frame>0, 1, 2, 3, 4, and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Reflex Epilepsy, Photosensitive</condition>
  <arm_group>
    <arm_group_label>PF-06372865 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17.5 milligram (mg) single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06372865 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52.5 mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Single dose</description>
    <arm_group_label>PF-06372865 dose level 1</arm_group_label>
    <arm_group_label>PF-06372865 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06372865 and placebo for lorazepam</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>2 mg single oral dose</description>
    <arm_group_label>Lorazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis and history of photoparoxysmal response on electroencephalogram (EEG)
             with or without a diagnosis of epilepsy for which subjects are taking up to 0 - 2
             concomitant antiepileptic drugs.

          -  Subjects currently taking antiepileptic drug(s) to be on a stable dose for 4 weeks
             prior to Screening Visit.

          -  A minimum average standardized photosensitive range (SPR) across all screening
             timepoints of 4 in the most sensitive eye condition and a non-zero average in at
             least one other eye condition.

        Exclusion Criteria:

          -  Subjects with a history of status epilepticus.

          -  Subjects who have experienced a generalized tonic-clonic convulsion in the past 6
             months, at the time of the initial screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consultants in Epilepsy &amp; Neurology, PLLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Department of Neurology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-7247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Comprehensive Epilepsy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the Univ of PA Pharmacy Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Comprehensive Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital EEG lab</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Investigational Drug Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Clinical Research Center (GCRC)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Epilepsy Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Hospital Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Department of Neurology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7431005&amp;StudyName=A%20Double%20Blind%2C%20Randomized%2C%20Cross-%20Over%20Study%20Examining%20Efficacy%20Of%20Pf-06372865%20In%20A%20Photosensitivity%20Epilepsy%20Study%20Using%20Lorazepam%20As%20A%20Positive%20Control</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>September 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Reflex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
